ATE493413T1 - Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3- - Google Patents
Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3-Info
- Publication number
- ATE493413T1 ATE493413T1 AT06744689T AT06744689T ATE493413T1 AT E493413 T1 ATE493413 T1 AT E493413T1 AT 06744689 T AT06744689 T AT 06744689T AT 06744689 T AT06744689 T AT 06744689T AT E493413 T1 ATE493413 T1 AT E493413T1
- Authority
- AT
- Austria
- Prior art keywords
- ethoxyethyl
- ethyl
- crystalline forms
- anhydrous crystalline
- methylaminoü
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68044505P | 2005-05-12 | 2005-05-12 | |
US68171105P | 2005-05-17 | 2005-05-17 | |
PCT/IB2006/001233 WO2006120552A2 (en) | 2005-05-12 | 2006-05-03 | ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE493413T1 true ATE493413T1 (de) | 2011-01-15 |
Family
ID=37106941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06744689T ATE493413T1 (de) | 2005-05-12 | 2006-05-03 | Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3- |
Country Status (24)
Country | Link |
---|---|
US (3) | US8227475B2 (ru) |
EP (1) | EP1881985B1 (ru) |
JP (2) | JP4271695B2 (ru) |
KR (1) | KR100939890B1 (ru) |
AT (1) | ATE493413T1 (ru) |
AU (1) | AU2006245416B2 (ru) |
BR (1) | BRPI0609225A2 (ru) |
CA (1) | CA2608018C (ru) |
CR (1) | CR9505A (ru) |
CY (1) | CY1111171T1 (ru) |
DE (1) | DE602006019231D1 (ru) |
DK (1) | DK1881985T3 (ru) |
EA (1) | EA012577B1 (ru) |
HK (1) | HK1116485A1 (ru) |
IL (1) | IL186693A (ru) |
MA (1) | MA29447B1 (ru) |
MX (1) | MX2007013215A (ru) |
NO (1) | NO20075258L (ru) |
NZ (1) | NZ564187A (ru) |
PL (1) | PL1881985T3 (ru) |
PT (1) | PT1881985E (ru) |
TN (1) | TNSN07414A1 (ru) |
TW (1) | TWI380986B (ru) |
WO (1) | WO2006120552A2 (ru) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7676953B2 (en) * | 2006-12-29 | 2010-03-16 | Signature Control Systems, Inc. | Calibration and metering methods for wood kiln moisture measurement |
WO2009050554A2 (en) * | 2007-10-19 | 2009-04-23 | Pfizer Inc. | Treatment of central nervous system disorders |
WO2012048330A2 (en) * | 2010-10-08 | 2012-04-12 | The Mclean Hospital Corporation | Treatment of motor neuron disease |
WO2012131539A1 (en) | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
TWI606049B (zh) | 2011-04-21 | 2017-11-21 | 原真股份有限公司 | 新穎激酶抑制劑 |
WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
CN102952138B (zh) * | 2011-08-17 | 2016-07-06 | 上海特化医药科技有限公司 | 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用 |
EP2751116B1 (en) | 2011-08-31 | 2016-10-12 | Pfizer Inc | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
JP6110937B2 (ja) | 2012-05-04 | 2017-04-05 | ファイザー・インク | APP、BACE1、およびBACE2の阻害剤としての複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
WO2014045162A1 (en) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
US9637491B2 (en) | 2012-10-19 | 2017-05-02 | Origenis Gmbh | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors |
MX2015005004A (es) * | 2012-10-23 | 2015-07-17 | Pfizer | Uso de un compuesto de pirazolo[4,3-d]pirimidina tetrasubstituida para tratar la nefropatia diabetica. |
EP2931731A1 (en) | 2012-12-11 | 2015-10-21 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
JP6162820B2 (ja) | 2012-12-19 | 2017-07-12 | ファイザー・インク | 炭素環式および複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
CA2897678A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
PE20151332A1 (es) | 2013-02-19 | 2015-09-20 | Pfizer | Compuestos de azabencimidazol |
WO2015049616A1 (en) | 2013-10-04 | 2015-04-09 | Pfizer Inc. | Novel bicyclic pyridinones as gamma-secretase modulators |
EP3126361B1 (en) | 2014-04-01 | 2019-11-06 | Pfizer Inc | Chromene and 1,1a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators |
MD20160105A2 (ru) | 2014-04-10 | 2017-03-31 | Pfizer Inc. | Амиды 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]-тиазин-8а(8Н)-ил-1,3-тиазол-4-ила |
JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
DK3177624T3 (da) | 2014-08-06 | 2019-07-01 | Pfizer | Imidazopyridazinforbindelser |
EP3253755B1 (en) | 2015-02-03 | 2020-08-26 | Pfizer Inc | Novel cyclopropabenzofuranyl pyridopyrazinediones |
CN107787322B (zh) | 2015-06-17 | 2023-07-07 | 辉瑞大药厂 | 三环化合物以及它们作为磷酸二酯酶抑制剂的用途 |
JP2018531924A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | テトラヒドロピラノ[3,4−d][1,3]オキサジン誘導体、およびbace阻害剤としてのその使用 |
JP2018531923A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | N−[2−(2−アミノ−6,6−二置換−4,4a,5,6−テトラヒドロピラノ[3,4−d][1,3]チアジン−8a(8H)−イル)−1,3−チアゾール−4−イル]アミド |
JP2018534251A (ja) | 2015-09-24 | 2018-11-22 | ファイザー・インク | Bace阻害剤として有用なn−[2−(3−アミノ−2,5−ジメチル−1,1−ジオキシド−5,6−ジヒドロ−2h−1,2,4−チアジアジン−5−イル)−1,3−チアゾール−4−イル]アミド |
AU2017223132B2 (en) | 2016-02-23 | 2019-12-05 | Pfizer Inc. | 6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
HUE054857T2 (hu) | 2016-07-01 | 2021-10-28 | Pfizer | 5,7-dihidro-pirrolo-piridinszármazékok neurológiai és neurodegeneratív betegségek kezelésére |
DK3642202T3 (da) | 2017-06-22 | 2023-01-30 | Pfizer | Dihydro-pyrrolo-pyridin-derivater |
CN112154145B (zh) | 2018-03-23 | 2023-10-17 | 辉瑞大药厂 | 哌嗪氮杂螺衍生物 |
WO2024118524A1 (en) | 2022-11-28 | 2024-06-06 | Cerevel Therapeutics, Llc | Azaindole compounds and their use as phosphodiesterase inhibitors |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
KR100390612B1 (ko) | 1997-04-25 | 2003-07-07 | 화이자 인코포레이티드 | 타입 5 시클릭 구아노신 3',5'-모노포스페이트포스포디에스테라제를 억제하는 성기능 장애 치료용피라졸로피리미디논 제조용 중간체의 제조 방법 |
ATE213246T1 (de) | 1997-11-12 | 2002-02-15 | 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren | |
ATE247117T1 (de) | 1998-04-20 | 2003-08-15 | Pfizer | Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen |
AU5995699A (en) | 1998-10-23 | 2000-05-15 | Bunnage, Mark Edward | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
DE19942474A1 (de) | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo[4,3-d]pyrimidine |
BR0014695A (pt) | 1999-10-11 | 2002-06-18 | Pfizer | 5-(2-substituìdo-5-heterociclilsulfonilpirid-3-il)-dihi dropirazolo[4,3-d]pirimidin-7-onas como inibidoras de fosfodiesterase |
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
DE10031584A1 (de) | 2000-06-29 | 2002-01-10 | Merck Patent Gmbh | 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine |
EE200300045A (et) | 2000-07-28 | 2004-12-15 | Pfizer Inc. | Kristalne ravimaine |
EP1348707B1 (en) * | 2002-03-28 | 2010-08-25 | Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO) | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy |
JP4015176B2 (ja) * | 2003-04-29 | 2007-11-28 | ファイザー・インク | 高血圧症の治療に有用な5,7−ジアミノピラゾロ4,3−ジピリミジン類 |
US7572799B2 (en) * | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
GB0327319D0 (en) * | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
GB0327323D0 (en) | 2003-11-24 | 2003-12-31 | Pfizer Ltd | Novel pharmaceuticals |
DK1742950T3 (da) | 2004-04-07 | 2009-03-16 | Pfizer Ltd | Pyrazolo-[4,3-D]-pyrimidiner |
CA2585557C (en) | 2004-10-28 | 2009-08-18 | Pharmacia & Upjohn Company Llc | Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors |
-
2006
- 2006-05-03 BR BRPI0609225-0A patent/BRPI0609225A2/pt not_active IP Right Cessation
- 2006-05-03 EP EP06744689A patent/EP1881985B1/en active Active
- 2006-05-03 PT PT06744689T patent/PT1881985E/pt unknown
- 2006-05-03 PL PL06744689T patent/PL1881985T3/pl unknown
- 2006-05-03 AT AT06744689T patent/ATE493413T1/de active
- 2006-05-03 NZ NZ564187A patent/NZ564187A/en not_active IP Right Cessation
- 2006-05-03 DK DK06744689.8T patent/DK1881985T3/da active
- 2006-05-03 US US11/913,091 patent/US8227475B2/en not_active Expired - Fee Related
- 2006-05-03 WO PCT/IB2006/001233 patent/WO2006120552A2/en not_active Application Discontinuation
- 2006-05-03 EA EA200702217A patent/EA012577B1/ru not_active IP Right Cessation
- 2006-05-03 AU AU2006245416A patent/AU2006245416B2/en not_active Ceased
- 2006-05-03 MX MX2007013215A patent/MX2007013215A/es active IP Right Grant
- 2006-05-03 KR KR1020077026098A patent/KR100939890B1/ko not_active IP Right Cessation
- 2006-05-03 CA CA2608018A patent/CA2608018C/en not_active Expired - Fee Related
- 2006-05-03 DE DE602006019231T patent/DE602006019231D1/de active Active
- 2006-05-11 JP JP2006132110A patent/JP4271695B2/ja not_active Expired - Fee Related
- 2006-05-11 TW TW095116704A patent/TWI380986B/zh not_active IP Right Cessation
-
2007
- 2007-10-12 NO NO20075258A patent/NO20075258L/no not_active Application Discontinuation
- 2007-10-16 IL IL186693A patent/IL186693A/en not_active IP Right Cessation
- 2007-11-09 CR CR9505A patent/CR9505A/es unknown
- 2007-11-09 TN TNP2007000414A patent/TNSN07414A1/fr unknown
- 2007-11-12 MA MA30362A patent/MA29447B1/fr unknown
-
2008
- 2008-06-20 HK HK08106870.4A patent/HK1116485A1/xx not_active IP Right Cessation
-
2009
- 2009-01-07 JP JP2009001627A patent/JP4996631B2/ja not_active Expired - Fee Related
-
2011
- 2011-02-08 CY CY20111100142T patent/CY1111171T1/el unknown
-
2012
- 2012-04-27 US US13/457,969 patent/US8796288B2/en not_active Expired - Fee Related
- 2012-04-27 US US13/457,886 patent/US8796287B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE493413T1 (de) | Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3- | |
ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
WO2007067506A3 (en) | 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors | |
NO20071915L (no) | Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer | |
MXPA05012025A (es) | Imidazo y tiazolopiridinas como inhibidores de cinasa jak3. | |
WO2006116148A3 (en) | (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse | |
TNSN07323A1 (en) | Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors | |
WO2003095455A3 (en) | Substituted pyrazolopyrimidines | |
UA86591C2 (ru) | Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе | |
WO2007002635A3 (en) | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions | |
RS53552B1 (en) | DERIVATI PIROLO [2,3-D] PIRIMIDINA KAO INHIBITORI PROTEIN KINAZE B | |
HK1113569A1 (en) | Pyrazolo | |
WO2007041130A3 (en) | Deazapurines useful as inhibitors of janus kinases | |
WO2004074244A3 (en) | Pyrimidine compounds | |
NO20074431L (no) | Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer | |
ZA200710379B (en) | Pyrrolopyridines useful as inhibitors of protein kinase | |
PT1379520E (pt) | Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b | |
WO2007068934A3 (en) | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit | |
WO2007120333A3 (en) | Tetracyclic kinase inhibitors | |
WO2007084424A3 (en) | Treatment of substance abuse | |
NO20075099L (no) | Alkynyl-pyrrolopyrmidiner og relaterte analoger som HSP90-inhibitorer | |
SG155939A1 (en) | Phosphoindoles as hiv inhibitors | |
NO20065898L (no) | 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner | |
TW200738723A (en) | 1-(1-(2-Ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid and salts thereof | |
WO2006124865A3 (en) | Biaryls derivatives useful as modulators of ion channels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1881985 Country of ref document: EP |